ArticleJournal of biomedical optics2026
Composing drug delivery with light distribution improvement: the use of dissolving microneedles in skin cancer with photodynamic therapy.
Article in Journal of biomedical optics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Significance: Dissolving microneedles (MN) have emerged as a promising platform for drug delivery, providing a minimally invasive approach to bypass the skin's natural barriers and enhance molecular penetration and diffusion. Their biocompatibility, user-friendly application, and ability to deliver precise therapeutic dosing make them particularly suitable for dermatological use. In addition to pharmacological benefits, dissolving MN possesses a geometric structure that enables optical waveguiding, thereby improving light penetration and distribution. Aim: We address a key limitation of photodynamic therapy (PDT): the limited penetration of light into biological tissues. PDT relies on activating photosensitizing agents with specific wavelengths of light to generate cytotoxic species, selectively targeting abnormal or diseased cells while minimizing effects on surrounding healthy tissue. Approach: Pyramidal dissolving MN arrays were fabricated from a biocompatible polymer and systematically characterized. Their light distribution profile under laser illumination was evaluated using image analysis. Results: Quantitative analysis of light distribution demonstrates that MN can simultaneously facilitate drug delivery and light distribution. Conclusions: This multifunctionality provides a synergistic therapeutic advantage, as localized drug release is complemented by optimized light delivery, thereby enhancing treatment outcomes. The dual-function platform has significant implications for PDT, enabling the design of integrated therapeutic systems that combine chemical and photonic modalities within a single, biodegradable device. Such systems may be particularly advantageous in resource-limited settings or outpatient care, where ease of use and effectiveness are essential. This strategy offers an approach to overcoming the limitations of conventional light-based therapies, supporting the development of more effective and accessible treatments for skin cancer and other dermatological conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.